42058-59-3

Basic information

• Product Name: 3-HYDROXYPHENYLACETIC ACID METHYL ESTER
• Synonyms: Benzeneacetic acid, 3-hydroxy-, methyl ester;Methyl m-hydroxyphenylacetate;METHYL 3-HYDROXYPHENYL ACETATE;3-HYDROXYPHENYLACETIC ACID METHYL ESTER;Methyl 2-(3-hydroxyphenyl)acetate;Methyl 3-hydroxybenzeneacetate;2-(3-Hydroxyphenyl)acetic acid methyl ester;Methyl 2-(3-hydroxyphenyl)
• CAS NO: 42058-59-3
• Molecular Formula: C₉H₁₀O₃
• Molecular Weight: 166.17
• Product Categories: Aromatic Esters
• Mol File: 42058-59-3.mol
• Article Data: 63

Chemical Properties

• Boiling Point: 146°C/14mmHg(lit.)
• Flash Point: 119.2 °C
• Appearance: /
• Density: 1.181 g/cm³
• Vapor Pressure: 0.00264mmHg at 25°C
• Refractive Index: 1.5340 to 1.5380
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Ethyl Acetate (Slightly)
• PKA: 9.61±0.10(Predicted)
• CAS DataBase Reference: 3-HYDROXYPHENYLACETIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-HYDROXYPHENYLACETIC ACID METHYL ESTER(42058-59-3)
• EPA Substance Registry System: 3-HYDROXYPHENYLACETIC ACID METHYL ESTER(42058-59-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 42058-59-3(Hazardous Substances Data)

Usage

Description

3-HYDROXYPHENYLACETIC ACID METHYL ESTER, also known as Methyl 3-Hydroxyphenylacetate, is a phenylacetic acid derivative with significant biological activities. It is characterized by its ability to act as a dual antagonist for CRTH2 and DP receptors, which are involved in various physiological processes.

Uses

Used in Pharmaceutical Industry:
3-HYDROXYPHENYLACETIC ACID METHYL ESTER is used as a pharmaceutical compound for its dual antagonistic properties against CRTH2 and DP receptors. This characteristic makes it a potential candidate for the development of drugs targeting conditions related to these receptors, such as asthma, allergic rhinitis, and other inflammatory diseases.
Used in Research and Development:
In the field of research and development, 3-HYDROXYPHENYLACETIC ACID METHYL ESTER serves as an important tool for studying the functions and interactions of CRTH2 and DP receptors. Its use in experimental settings can help researchers better understand the underlying mechanisms of various diseases and develop targeted therapies.
Used in Drug Design and Optimization:
3-HYDROXYPHENYLACETIC ACID METHYL ESTER is used as a starting point for the design and optimization of new drugs with improved efficacy and safety profiles. Its dual antagonistic properties can be leveraged to create more effective medications for treating conditions related to CRTH2 and DP receptor dysregulation.

InChI:InChI=1/C9H10O3/c1-12-9(11)6-7-3-2-4-8(10)5-7/h2-5,10H,6H2,1H3

Upstream product

• 93273-66-6 methyl 3-<2-(methoxycarbonyl)benzyloxy>phenylacetate 
• 20667-76-9 3-methyl-1-p-tolyltriazene 
• 621-37-4 m-hydroxyphenylacetic acid 
• 101-41-7 benzeneacetic acid methyl ester 
• 67-56-1 methanol 
• 149-73-5 trimethyl orthoformate 
• 55690-19-2 3-(2-carboxybenzyloxy)phenylacetic acid 
• 62969-42-0 3-benzyloxy-phenylacetic acid methyl ester 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 160721-41-5 4-<3-<(methoxy)methoxy>phenyl>acetic acid 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 1026491-17-7 [3-(Thiophen-3-yloxy)-phenyl]-acetic acid methyl ester 
• 104325-56-6 methyl 3-(2-quinolinylmethoxy)benzeneacetate 
• 123723-91-1 [3-(Benzothiazol-2-ylmethoxy)-phenyl]-acetic acid methyl ester 
• 139988-02-6 methyl 3-ethoxyphenylacetate 
• 123723-89-7 [3-(1-Methyl-1H-benzoimidazol-2-ylmethoxy)-phenyl]-acetic acid methyl ester 
• 153938-42-2 methyl 3-(2-phthalimidoethoxy)phenyl acetate 
• 138830-31-6 3-(tetradecyloxy)benzeneacetic acid, methyl ester 
• 82340-98-5 methyl 2-[3-(2-nitrophenoxy)phenyl]acetate 
• 13398-94-2 2-(3-hydroxyphenyl)ethanol 
• 189019-37-2 3-(2-hydroxy-2-methyl-propyl)-phenol 
• 147283-87-2 methyl [3-[[(trifluoromethyl)sulfonyl]oxy]phenyl]-acetate 
• 228579-12-2 methyl [3-(3-bromopropoxy)phenyl]acetate 
• 250339-82-3 methyl 2-[3-(3-nitrophenoxy)phenyl]acetate 
• 220299-54-7 N-methyl-(3-hydroxyphenyl)acetamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel FXR agonists based on auraptene

Farnesoid X receptor (FXR) has been considered as an attractive target for metabolic disorder and liver injury, while many current FXR agonists suffer from undesirable side effects, such as pruritus. Therefore, it is urgent to develop new structure types different from current FXR agonists. In this study, a series of structural optimizations were introduced to displace the unstable coumarin and geraniol scaffolds of auraptene (AUR), a novel and safe FXR agonist. All of these efforts led to the identification of compound 14, a potent FXR agonist with nearly fourfold higher activity than AUR. Molecular modeling study suggested that compound 14 fitted well with binding pocket, and formed the key ionic bond with His291 and Arg328. In acetaminophen-induced acute liver injury model, compound 14 exerts better therapeutic effect than that of AUR, which highlighting its pharmacological potential in the treatment of drug-induced liver injury.

Synthesis and Absolute Configuration of Habiterpenol

The synthesis of habiterpenol, a G2 checkpoint inhibitor, was achieved through the stereoselective Ti(III)-mediated radical cyclization of a β-epoxide as the key reaction. Moreover, the absolute configuration of habiterpenol was determined.

Dynamic Combinatorial Chemistry to Identify Binders of ThiT, an S-Component of the Energy-Coupling Factor Transporter for Thiamine

We applied dynamic combinatorial chemistry (DCC) to identify ligands of ThiT, the S-component of the energy-coupling factor (ECF) transporter for thiamine in Lactococcus lactis. We used a pre-equilibrated dynamic combinatorial library (DCL) and saturation-transfer difference (STD) NMR spectroscopy to identify ligands of ThiT. This is the first report in which DCC is used for fragment growing to an ill-defined pocket, and one of the first reports for its application with an integral membrane protein as target.